Literature DB >> 18854269

Detecting high-grade cervical disease on ASC-H cytology: role of BD ProEx C and Digene Hybrid Capture II HPV DNA testing.

Momin T Siddiqui1, Cynthia Cohen, Aziza Nassar.   

Abstract

The BD ProEx C stain (BD Diagnostics-Tripath, Burlington, NC) detects 2 molecular markers known to be overexpressed in cervical squamous cell carcinoma, minichromosome maintenance protein 2 and topoisomerase II. This study was conducted to evaluate this stain detecting high-grade cervical disease, and results were compared with high-risk HPV (hr-HPV) status and histologic biopsy diagnosis in Papanicolaou tests with atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H) cytologic results. Cervical cytology specimens were collected in BD SurePath preservative (BD Diagnostics-Tripath), and 100 specimens with a diagnosis of ASC-H were included in the study. A second BD SurePath slide, prepared from the residual cellular material from these ASC-H cases, was immunostained using the BD ProEx C reagent. Nuclear staining of ASC-H cells was considered a positive result. The sensitivity for BD ProEx C for detecting cervical intraepithelial neoplasia 2 or worse was 98.8% and for hr-HPV was 71.1%, whereas specificity values were 82.4% and 64.7%, respectively. BD ProEx C has potential as a marker for detection of high-grade disease in patients with ASC-H cytologic results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18854269     DOI: 10.1309/AJCPWW6V2KGXODUI

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  10 in total

1.  MOLECULAR MARKERS OF EARLY CERVICAL NEOPLASIA.

Authors:  Alvaro P Pinto; Christopher P Crum; Michelle S Hirsch
Journal:  Diagn Histopathol (Oxf)       Date:  2010-10-01

Review 2.  Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts.

Authors:  Vikrant V Sahasrabuddhe; Patricia Luhn; Nicolas Wentzensen
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

3.  Atypical squamous cells, cannot exclude high grade squamous intraepithelial (ASC-H) in HIV-positive women.

Authors:  Pam Michelow; Ingrid Hartman; Doreen Schulze; Stella Lamla-Hillie; Sophie Williams; Simon Levin; Cynthia Firnhaber
Journal:  Cytojournal       Date:  2010-06-12       Impact factor: 2.091

4.  p16 is superior to ProEx C in identifying high-grade squamous intraepithelial lesions (HSIL) of the anal canal.

Authors:  Rajeev Bala; Benjamin A Pinsky; Andrew H Beck; Christina S Kong; Mark L Welton; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2013-05       Impact factor: 6.394

5.  Role of protein biomarkers in the detection of high-grade disease in cervical cancer screening programs.

Authors:  Charlotte A Brown; Johnannes Bogers; Shaira Sahebali; Christophe E Depuydt; Frans De Prins; Douglas P Malinowski
Journal:  J Oncol       Date:  2012-02-28       Impact factor: 4.375

6.  Immunocytoexpression profile of ProExC in smears interpreted as ASC-US, ASC-H, and cervical intraepithelial lesion.

Authors:  Zeynep Tosuner; İlknur Türkmen; Sema Arici; Cavide Sönmez; Seval Turna; Öykü Onaran
Journal:  J Cytol       Date:  2017 Jan-Mar       Impact factor: 1.000

Review 7.  ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review.

Authors:  Gerardo Botti; Maria Gabriella Malzone; Elvira La Mantia; Micaela Montanari; Daniela Vanacore; Sabrina Rossetti; Vincenzo Quagliariello; Carla Cavaliere; Rossella Di Franco; Luigi Castaldo; Gianluca Ametrano; Francesca Cappuccio; Francesco Jacopo Romano; Raffaele Piscitelli; Maria Filomena Pepe; Carmine D'Aniello; Gaetano Facchini
Journal:  Int J Med Sci       Date:  2017-04-21       Impact factor: 3.738

Review 8.  Role of immunocytochemistry in cervical cancer screening.

Authors:  Vinod B Shidham
Journal:  Cytojournal       Date:  2022-06-14       Impact factor: 2.345

9.  Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening.

Authors:  Sonya Naryshkin; R Marshall Austin
Journal:  Drug Healthc Patient Saf       Date:  2012-11-02

10.  Diagnostic sensitivity for invasive cervical carcinoma of high risk HPV tests performed on SurePath™ liquid-based pap specimens.

Authors:  Keith V Nance
Journal:  Drug Healthc Patient Saf       Date:  2013-03-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.